Bellerophon Therapeutics (BLPH) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Bellerophon Therapeutics (BLPH) Tops Q2 EPS by 12c

Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update

August 9, 2016 6:33 AM EDT

WARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update.

This quarter, we made important progress on our development plans across our clinical pipeline, stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. As planned, in June we enrolled our first patient in our Phase 3 INOvation-1 clinical trial to treat Pulmonary Arterial Hypertension, or PAH, under an FDA-granted Special Protocol Assessment. We also commenced a trial with our INOpulse therapy to treat pulmonary... More